Literature DB >> 18751855

The Hospital for the Ruptured and Crippled: William Bradley Coley, third Surgeon-in-Chief 1925-1933.

David B Levine1.   

Abstract

In January 1925, the Board of Managers of the New York Society for the Relief of the Ruptured and Crippled appointed William Bradley Coley, M.D., age 63, Surgeon-in-Chief of the Hospital for the Ruptured and Crippled (R & C) to succeed Virgil P. Gibney who submitted his resignation the month before. It would be the first time a general surgeon held that position at the oldest orthopedic hospital in the nation, now known as Hospital for Special Surgery (HSS). Coley had been on staff for 36 years and was world famous for introducing use of toxins to treat malignant tumors, particularly sarcomas. A graduate of Yale College and Harvard Medical College, Coley interned at New York Hospital and was appointed, soon after, to the staff of the New York Cancer Hospital (now Memorial Sloan Kettering Cancer Center) located at that time at 106th Street on the West Side of New York. With his mentor Dr. William Bull, Coley perfected the surgical treatment of hernias at R & C. He was instrumental in raising funds for his alma maters, Yale, Harvard and Memorial Hospital. His crusade in immunology as a method of treatment for malignant tumors later fell out of acceptance in the medical establishment. After his death in 1936, an attempt to revive interest in use of immunotherapy for inoperable malignancies was carried out by his daughter, Helen Coley Nauts, who pursued this objective until her death at age 93 in 2000. Coley's health deteriorated in his later years, and in 1933, he resigned as chief of Bone Tumors at Memorial Hospital and Surgeon-in-Chief at R & C, being succeeded at Ruptured and Crippled as Surgeon-in-Chief by Dr. Eugene H. Pool. William Bradley Coley died of intestinal infarction in 1936 and was buried in Sharon, Connecticut.

Entities:  

Year:  2007        PMID: 18751855      PMCID: PMC2504278          DOI: 10.1007/s11420-007-9063-2

Source DB:  PubMed          Journal:  HSS J        ISSN: 1556-3316


  8 in total

1.  Hospital for special surgery. A brief review of its development and current position.

Authors:  P D Wilson; D B Levine
Journal:  Clin Orthop Relat Res       Date:  2000-05       Impact factor: 4.176

2.  WILLIAM BRADLEY COLEY 1862-1936.

Authors:  C G Burdick
Journal:  Ann Surg       Date:  1937-01       Impact factor: 12.969

3.  Hospital for Special Surgery: origin and early history first site 1863-1870.

Authors:  David B Levine
Journal:  HSS J       Date:  2005-09

4.  Gibney as Surgeon-in-Chief: the earlier years, 1887-1900.

Authors:  David B Levine
Journal:  HSS J       Date:  2006-09

5.  The Hospital for the Ruptured and Crippled, entering the twentieth century, ca. 1900 to 1912.

Authors:  David B Levine
Journal:  HSS J       Date:  2007-02

6.  II. Observations upon the Operative Treatment of Hernia at the Hospital for the Ruptured and Crippled.

Authors:  W T Bull; W B Coley
Journal:  Ann Surg       Date:  1898-11       Impact factor: 12.969

7.  The Hospital for the Ruptured and Crippled: Knight to Gibney, 1870-1887.

Authors:  David B Levine
Journal:  HSS J       Date:  2006-02

8.  The Hospital for the Ruptured and Crippled moves east on 42nd Street 1912 to 1925.

Authors:  D B Levine
Journal:  HSS J       Date:  2007-09
  8 in total
  9 in total

Review 1.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

2.  The Hospital for Special Surgery affiliates with Cornell University Medical College and New York Hospital, 1951; Philip D. Wilson retires as Surgeon-in-Chief, 1955.

Authors:  David B Levine
Journal:  HSS J       Date:  2009-06-09

3.  The Hospital for the Ruptured and Crippled Eugene H. Pool, fourth Surgeon-in-Chief 1933-1935 followed by Philip D. Wilson, fifth Surgeon-in-Chief 1935.

Authors:  David B Levine
Journal:  HSS J       Date:  2008-07-18

Review 4.  Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Authors:  Julia Kravchenko; Emanuela Corsini; Marc A Williams; William Decker; Masoud H Manjili; Takemi Otsuki; Neetu Singh; Faha Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson; Leroy Lowe; H Kim Lyerly
Journal:  Carcinogenesis       Date:  2015-05-22       Impact factor: 4.944

Review 5.  Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.

Authors:  Yiran Zhang; Meng Zhang; Yifei Jiang; Xiulian Li; Yanli He; Pengjiao Zeng; Zhihua Guo; Yajing Chang; Heng Luo; Yong Liu; Cui Hao; Hua Wang; Guoqing Zhang; Lijuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-24       Impact factor: 4.553

Review 6.  Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.

Authors:  William K Decker; Rodrigo F da Silva; Mayra H Sanabria; Laura S Angelo; Fernando Guimarães; Bryan M Burt; Farrah Kheradmand; Silke Paust
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

Review 7.  Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations.

Authors:  Gunver S Kienle
Journal:  Glob Adv Health Med       Date:  2012-03

Review 8.  William Bradley Coley, MD, and the phenomenon of spontaneous regression.

Authors:  Leonard F Vernon
Journal:  Immunotargets Ther       Date:  2018-04-23

Review 9.  Defining trained immunity and its role in health and disease.

Authors:  Mihai G Netea; Jorge Domínguez-Andrés; Luis B Barreiro; Triantafyllos Chavakis; Maziar Divangahi; Elaine Fuchs; Leo A B Joosten; Jos W M van der Meer; Musa M Mhlanga; Willem J M Mulder; Niels P Riksen; Andreas Schlitzer; Joachim L Schultze; Christine Stabell Benn; Joseph C Sun; Ramnik J Xavier; Eicke Latz
Journal:  Nat Rev Immunol       Date:  2020-03-04       Impact factor: 53.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.